Stryker (SYK) Stock Buyback History
TTM buyback yield 0.02% · Shareholder yield (TTM) 0.02%.
SYK
TTM buyback yield
0.02%
Shareholder yield (TTM)
0.02%
5Y share count change
0.5%
TTM buyback spend
$31.00M
SBC coverage (TTM)
0.28x
YoY change in spend
-100.0%
5Y CAGR of spend
-100.0%
Peak year (2008)
$1.00B
Cumulative spend
$4.86B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Stryker (SYK) repurchased about $31.00M of stock over the trailing twelve months.
- Diluted share count is roughly flat (0.5%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
- TTM buyback ÷ stock-based-comp ratio of 0.28× — repurchases only partially offset SBC dilution.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 1% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $243.00M | −$243.00M | 0.38B | -0.9% | — |
| 2024 | $195.00M | $229.00M | −$34.00M | 0.39B | 0.5% | 0.14% |
| 2023 | $155.00M | $205.00M | −$50.00M | 0.38B | 0.4% | 0.14% |
| 2022 | $122.00M | $168.00M | −$46.00M | 0.38B | -0.0% | 0.13% |
| 2021 | $114.00M | $171.00M | −$57.00M | 0.38B | 0.5% | 0.11% |
| 2020 | $110.00M | $142.00M | −$32.00M | 0.38B | 0.1% | 0.12% |
| 2019 | $307.00M | $127.00M | $180.00M | 0.38B | -0.1% | 0.39% |
| 2018 | $300.00M | $119.00M | $181.00M | 0.38B | 0.1% | 0.51% |
| 2017 | $230.00M | $113.00M | $117.00M | 0.38B | 0.4% | 0.40% |
| 2016 | $13.00M | $97.00M | −$84.00M | 0.38B | -0.6% | 0.03% |
| 2015 | $700.00M | $86.00M | $614.00M | 0.38B | -0.5% | 2.01% |
| 2014 | $100.00M | $77.00M | $23.00M | 0.38B | 0.2% | 0.28% |
| 2013 | $317.00M | $76.00M | $241.00M | 0.38B | -0.2% | 1.11% |
| 2012 | $108.00M | $75.00M | $33.00M | 0.38B | -1.7% | 0.52% |
| 2011 | $622.00M | $75.00M | $547.00M | 0.39B | -2.5% | 3.28% |
| 2010 | $425.50M | $68.80M | $356.70M | 0.40B | 0.0% | 2.03% |
| 2009 | $0.00 | $62.30M | −$62.30M | 0.40B | -3.4% | — |
| 2008 | $1.00B | $65.50M | $934.50M | 0.41B | -0.9% | 6.31% |
| 2007 | $0.00 | $61.30M | −$61.30M | 0.42B | 1.4% | — |
| 2006 | $0.00 | $49.40M | −$49.40M | 0.41B | 0.2% | — |
| 2005 | $0.00 | $0.00 | $0.00 | 0.41B | 0.4% | — |
| 2004 | $0.00 | $0.00 | $0.00 | 0.41B | -3.4% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 0.42B | -0.7% | — |
| 2002 | $0.00 | $0.00 | $0.00 | 0.43B | 7.1% | — |
| 2001 | $0.00 | $0.00 | $0.00 | 0.40B | -0.8% | — |
| 2000 | $0.00 | $0.00 | $0.00 | 0.40B | 3.6% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.39B | -1.4% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.39B | 0.5% | — |
| 1997 | $25.60M | $0.00 | $25.60M | 0.39B | -0.7% | — |
| 1996 | $15.10M | $0.00 | $15.10M | 0.39B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $3.10M | $0.00 | $3.10M | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1989 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Stryker (SYK) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Stryker (SYK)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Stryker (SYK)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | -$195.00M | ||
| 2024 | $195.00M | +25.8% | +$40.00M | ||
| 2023 | $155.00M | +27.0% | +$33.00M | ||
| 2022 | $122.00M | +7.0% | +$8.00M | ||
| 2021 | $114.00M | +3.6% | +$4.00M | ||
| 2020 | $110.00M | -64.2% | -$197.00M | ||
| 2019 | $307.00M | +2.3% | +$7.00M | ||
| 2018 | $300.00M | +30.4% | +$70.00M | ||
| 2017 | $230.00M | +1669.2% | +$217.00M | ||
| 2016 | $13.00M | -98.1% | -$687.00M | ||
| 2015 | $700.00M | +600.0% | +$600.00M | ||
| 2014 | $100.00M | -68.5% | -$217.00M | ||
| 2013 | $317.00M | +193.5% | +$209.00M | ||
| 2012 | $108.00M | -82.6% | -$514.00M | ||
| 2011 | $622.00M | +46.2% | +$196.50M | ||
| 2010 | $425.50M | — | +$425.50M | ||
| 2009 | $0 | -100.0% | -$1.00B | ||
| 2008 | $1.00B | — | +$1.00B | ||
| 2007 | $0 | — | $0 | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | — | $0 | ||
| 2003 | $0 | — | $0 | ||
| 2002 | $0 | — | $0 | ||
| 2001 | $0 | — | $0 | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | -100.0% | -$25.60M | ||
| 1997 | $25.60M | +69.5% | +$10.50M | ||
| 1996 | $15.10M | — | +$15.10M | ||
| 1995 | $0 | -100.0% | -$3.10M | ||
| 1994 | $3.10M | — | +$3.10M | ||
| 1993 | $0 | — | $0 | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | $0 | ||
| 1990 | $0 | — | $0 | ||
| 1989 | $0 | — | — |
The 2025 reading of Stryker (SYK) buyback spend is $0 – plunged 100.0% year-over-year.
Stryker buyback spend compound annual growth for the 2020–2025 (5 years) window is -100.0%, with a net decline across the window.
Stryker buyback spend peaked at $1.00B in 2008; the latest annual figure is $0 in 2025 (100.0% below peak).
2008 marks the peak buyback spend at $1.00B, with the historical low of $0 recorded in 1989.
Within Healthcare, Stryker (SYK) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
Stryker Buyback Spend 2025: $0
Stryker buyback spend in 2025 was $0, plunged 100.0% below 2024.
Stryker Buyback Spend 2024: $195.00M
Stryker buyback spend in 2024 was $195.00M, grew 25.8% from 2023.
Stryker Buyback Spend 2023: $155.00M
Stryker buyback spend in 2023 was $155.00M, grew 27.0% from 2022.
Stryker Buyback Spend 2022: $122.00M
Stryker buyback spend in 2022 was $122.00M, grew 7.0% from 2021.
Stryker Buyback Spend 2021: $114.00M
Stryker buyback spend in 2021 was $114.00M.
See more financial history for Stryker (SYK).
Sector peers by buyback spend
Companies in the same sector as Stryker, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.28×.
Capital allocation mix
How Stryker splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.27B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Stryker's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Stryker buy back its own stock?
Yes, Stryker (SYK) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Stryker spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $31.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Stryker's buyback yield?
TTM buyback yield is about 0.02% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Stryker's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.02% combined (TTM-based where available).
Is Stryker diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Stryker's share count changed?
Diluted weighted average shares changed by about 0.5% over roughly five fiscal years (annual income statement data).
What is Stryker's buyback spend?
Latest reported buyback spend for Stryker (SYK) is $31.00M (period ending March 31, 2026).
How has Stryker buyback spend changed year-over-year?
Stryker (SYK) buyback spend changed -100.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Stryker buyback spend?
Stryker (SYK) buyback spend compound annual growth rate is -100.0% over the most recent 5 years available.
When did Stryker buyback spend hit its highest annual value?
Stryker buyback spend reached its highest annual value of $1.00B in 2008.
What was Stryker buyback spend in 2024?
Stryker (SYK) buyback spend in 2024 was $195.00M.
What was Stryker buyback spend in 2025?
Stryker (SYK) buyback spend in 2025 was $0.
Explore more
SYK Overview
Company profile, financial tools, and key metrics
SYK Revenue Counter
Earns $801.31 every second. See per minute, hour, and day.
SYK Earnings Counter
Earns $105.82 per second net profit. See per minute, hour, and day.
SYK Economic Scale
Exceeds Haiti's GDP. Compare with world economies.
SYK What If Invested
What if you had invested $1,000? See historical returns from any date.
SYK How It Makes Money
Discover visual breakdown of $25.27B in revenue — where it comes from and where it goes.
SYK Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
SYK Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
SYK Daily Price Character
Balanced · 47.3% historical win rate (green days). Streaks & record days.
SYK Stock Split History
9 splits on record. Dates, ratios, and cumulative multiple.
SYK Dividend Profile
Yield: 1.07%. Safety: 7/8. See full history.
SYK Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
SYK Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
SYK Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
SYK Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.